WhiteSwell, a frontrunner in the treatment of acute decompensated heart failure (ADHF), has shared optimistic initial results from its continuing DELTA-HF trial centered around the WhiteSwell eLym System. Unveiled at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio, the eLym System emerges as a minimally invasive catheter-based system that aims to remove surplus fluid from body tissues and organs alongside diuretic removal of vascular fluid. Targeting the body’s principal lymphatic vessel, the system establishes pressure conditions conducive to the drainage abilities of an overburdened lymphatic system.

In the trial, nine hospitalized patients underwent eLym therapy combined with diuretic treatment, while six patients received the standard care with loop diuretics alone. The findings are promising:

• The eLym System was safely and efficiently used, with an average treatment time of 24 hours.
• No adverse events related to the procedure, device, or therapy were observed.
• Patients treated with the eLym System alongside loop diuretics lost an average of 6.0±4.6 kg from admission to discharge, with preserved kidney functionality.
• In comparison, the loop diuretic-only group exhibited a weight loss averaging 3.3±3.7 kg.

Dr. William Abraham, affiliated with The Ohio State University Wexner Medical Center, highlighted the pressing challenge of decongesting patients with decompensated heart failure. Praising WhiteSwell’s approach, he noted the simultaneous addressing of interstitial tissue and intravascular decongestion. Dr. Zviad Kereselidze from Tbilisi Heart Center shared his enthusiasm for WhiteSwell’s catheter-based system, emphasizing its efficacy even in challenging ADHF cases.

As WhiteSwell continues its exploration of this groundbreaking approach in the DELTA-HF Trial, the medical community awaits further revelations with bated breath.

In a nutshell, the introduction of WhiteSwell’s eLym System in the treatment of ADHF marks a potential paradigm shift. Offering a dual advantage of targeted decongestion and preserved kidney functionality, the system may redefine ADHF therapeutic approaches in the coming years.

Key Insights:

• WhiteSwell unveils initial positive results from its ongoing DELTA-HF trial.
• The eLym System, presented at the HFSA Annual Scientific Meeting 2023, offers a new treatment approach for ADHF.
• eLym System combined with diuretic therapy proves more effective than standard loop diuretics.
• Expert voices underscore the significance of WhiteSwell’s innovative treatment.

  Dr. William Abraham, heart failure, USA, WhiteSwell, WhiteSwell eLym System